Creating zinc monkey wrenches in the treatment of epigenetic disorders

Jay Hans Kalin, Kyle Vincent Butler, Alan Paul Kozikowski

Research output: Contribution to journalArticle

Abstract

The approval of suberoylanilide hydroxamic acid by the FDA for the treatment of cutaneous T-cell lymphoma in October, 2006 sparked a dramatic increase in the development of inhibitors for the class of enzymes known as the histone deacetylases (HDACs). In recent years, a large number of combination therapies involving histone deacetylase inhibitors (HDACIs) have been developed for the treatment of a variety of malignancies and neurodegenerative disorders. Promising evidence has been reported for the treatment of pancreatic cancer, prostate cancer, and leukemia as well as a number of other previously difficult to treat cancers. Drug combination approaches have also shown promise for the treatment of mood disorders including bipolar disorder and depression. In addition to these drug combination approaches, HDACIs alone have demonstrated effectiveness in the treatment of Parkinson's disease, Alzheimer's disease, Rubinstein-Taybi syndrome, Rett syndrome, Friedreich's ataxia, Huntington's disease, multiple sclerosis, anxiety, and schizophrenia. Adverse inflammatory affects observed with traumatic brain injury and arthritis have also been alleviated by treatment with certain HDACIs. Based on the diverse utility and wide range of mechanistic actions observed with this class of drugs, the future development of better drug combination therapies and more selective HDACIs is warranted.

Original languageEnglish (US)
Pages (from-to)263-271
Number of pages9
JournalCurrent Opinion in Chemical Biology
Volume13
Issue number3
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Hand tools
Histone Deacetylase Inhibitors
Epigenomics
Haplorhini
Zinc
Drug Combinations
Bipolar Disorder
Drug therapy
Histone Deacetylases
T-cells
Prostatic Neoplasms
Therapeutics
Rubinstein-Taybi Syndrome
Friedreich Ataxia
Rett Syndrome
Cutaneous T-Cell Lymphoma
Brain
Huntington Disease
Enzyme Inhibitors
Combination Drug Therapy

ASJC Scopus subject areas

  • Biochemistry
  • Analytical Chemistry

Cite this

Creating zinc monkey wrenches in the treatment of epigenetic disorders. / Kalin, Jay Hans; Butler, Kyle Vincent; Kozikowski, Alan Paul.

In: Current Opinion in Chemical Biology, Vol. 13, No. 3, 06.2009, p. 263-271.

Research output: Contribution to journalArticle

Kalin, Jay Hans ; Butler, Kyle Vincent ; Kozikowski, Alan Paul. / Creating zinc monkey wrenches in the treatment of epigenetic disorders. In: Current Opinion in Chemical Biology. 2009 ; Vol. 13, No. 3. pp. 263-271.
@article{2de33209557c476193ab8a10097927c1,
title = "Creating zinc monkey wrenches in the treatment of epigenetic disorders",
abstract = "The approval of suberoylanilide hydroxamic acid by the FDA for the treatment of cutaneous T-cell lymphoma in October, 2006 sparked a dramatic increase in the development of inhibitors for the class of enzymes known as the histone deacetylases (HDACs). In recent years, a large number of combination therapies involving histone deacetylase inhibitors (HDACIs) have been developed for the treatment of a variety of malignancies and neurodegenerative disorders. Promising evidence has been reported for the treatment of pancreatic cancer, prostate cancer, and leukemia as well as a number of other previously difficult to treat cancers. Drug combination approaches have also shown promise for the treatment of mood disorders including bipolar disorder and depression. In addition to these drug combination approaches, HDACIs alone have demonstrated effectiveness in the treatment of Parkinson's disease, Alzheimer's disease, Rubinstein-Taybi syndrome, Rett syndrome, Friedreich's ataxia, Huntington's disease, multiple sclerosis, anxiety, and schizophrenia. Adverse inflammatory affects observed with traumatic brain injury and arthritis have also been alleviated by treatment with certain HDACIs. Based on the diverse utility and wide range of mechanistic actions observed with this class of drugs, the future development of better drug combination therapies and more selective HDACIs is warranted.",
author = "Kalin, {Jay Hans} and Butler, {Kyle Vincent} and Kozikowski, {Alan Paul}",
year = "2009",
month = "6",
doi = "10.1016/j.cbpa.2009.05.007",
language = "English (US)",
volume = "13",
pages = "263--271",
journal = "Current Opinion in Chemical Biology",
issn = "1367-5931",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Creating zinc monkey wrenches in the treatment of epigenetic disorders

AU - Kalin, Jay Hans

AU - Butler, Kyle Vincent

AU - Kozikowski, Alan Paul

PY - 2009/6

Y1 - 2009/6

N2 - The approval of suberoylanilide hydroxamic acid by the FDA for the treatment of cutaneous T-cell lymphoma in October, 2006 sparked a dramatic increase in the development of inhibitors for the class of enzymes known as the histone deacetylases (HDACs). In recent years, a large number of combination therapies involving histone deacetylase inhibitors (HDACIs) have been developed for the treatment of a variety of malignancies and neurodegenerative disorders. Promising evidence has been reported for the treatment of pancreatic cancer, prostate cancer, and leukemia as well as a number of other previously difficult to treat cancers. Drug combination approaches have also shown promise for the treatment of mood disorders including bipolar disorder and depression. In addition to these drug combination approaches, HDACIs alone have demonstrated effectiveness in the treatment of Parkinson's disease, Alzheimer's disease, Rubinstein-Taybi syndrome, Rett syndrome, Friedreich's ataxia, Huntington's disease, multiple sclerosis, anxiety, and schizophrenia. Adverse inflammatory affects observed with traumatic brain injury and arthritis have also been alleviated by treatment with certain HDACIs. Based on the diverse utility and wide range of mechanistic actions observed with this class of drugs, the future development of better drug combination therapies and more selective HDACIs is warranted.

AB - The approval of suberoylanilide hydroxamic acid by the FDA for the treatment of cutaneous T-cell lymphoma in October, 2006 sparked a dramatic increase in the development of inhibitors for the class of enzymes known as the histone deacetylases (HDACs). In recent years, a large number of combination therapies involving histone deacetylase inhibitors (HDACIs) have been developed for the treatment of a variety of malignancies and neurodegenerative disorders. Promising evidence has been reported for the treatment of pancreatic cancer, prostate cancer, and leukemia as well as a number of other previously difficult to treat cancers. Drug combination approaches have also shown promise for the treatment of mood disorders including bipolar disorder and depression. In addition to these drug combination approaches, HDACIs alone have demonstrated effectiveness in the treatment of Parkinson's disease, Alzheimer's disease, Rubinstein-Taybi syndrome, Rett syndrome, Friedreich's ataxia, Huntington's disease, multiple sclerosis, anxiety, and schizophrenia. Adverse inflammatory affects observed with traumatic brain injury and arthritis have also been alleviated by treatment with certain HDACIs. Based on the diverse utility and wide range of mechanistic actions observed with this class of drugs, the future development of better drug combination therapies and more selective HDACIs is warranted.

UR - http://www.scopus.com/inward/record.url?scp=67649975232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649975232&partnerID=8YFLogxK

U2 - 10.1016/j.cbpa.2009.05.007

DO - 10.1016/j.cbpa.2009.05.007

M3 - Article

C2 - 19541531

AN - SCOPUS:67649975232

VL - 13

SP - 263

EP - 271

JO - Current Opinion in Chemical Biology

JF - Current Opinion in Chemical Biology

SN - 1367-5931

IS - 3

ER -